The security, immunogenicity, and efficacy of the mRNA-1273 vaccine in youngsters aged 6-11

In a current research revealed in The New England Journal of Medicine, researchers evaluated the security, immunogenicity, and efficacy of the messenger ribonucleic acid (mRNA)-1273 vaccine in youngsters.

Study: Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. Image Credit: Uryupina Nadezhda/Shutterstock
Research: Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age. Picture Credit score: Uryupina Nadezhda/Shutterstock


Like adults, coronavirus illness 2019 (COVID-19) has disrupted the lives of youngsters, affecting their educational life and general well-being. Furthermore, extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an infection could cause a multisystem inflammatory syndrome in children (MIS-C), necessitating safety by way of vaccination. Subsequently, the US Meals and Drug Administration (FDA) just lately issued provisional emergency use authorization (EUA) for the mRNA-1273 vaccine for kids in nations exterior the US.

Concerning the research

The present part II-III scientific trial research, termed the KIDCove trial, was accomplished in two elements. Half one of many trial was open-label for dose choice, whereas half two was a blinded, placebo trial evaluating the enlargement of the chosen dose.

Primarily based on the security and immunogenicity outcomes of half 1  of the trial, researchers chosen the 50-μg dosage stage for half 2. Subsequent, they randomly assigned 4016 eligible youngsters in a ratio of three:1 utilizing a centralized interactive response expertise system. These youngsters obtained two doses of mRNA-1273 vaccine or placebo of fifty μg every at an interval of 28 days. The workforce then adopted for 82 days on common after the primary injection.

There have been three age-based cohorts of the youngsters taking part within the trial – 6 months to 23 months, two to 5 years, and 6 to 11 years. These youngsters have been enrolled at 79 websites within the US and eight websites in Canada. For the reason that research inhabitants was so numerous, the outcomes of this massive trial could possibly be generalized to numerous populations of youngsters.

The researchers generated the security profile of the mRNA1273 vaccine in youngsters in comparison with younger adults taking part in a associated part III scientific trial. Extra particularly, they ascertained that the elicited immune response in youngsters was corresponding to adults and never inferior.

Research findings

The authors famous solely low-grade, transient antagonistic occasions in 4016 youngsters who obtained a 50-μg dose. These antagonistic occasions generally included injection-site ache, headache, and fatigue. By the closing date of the current trial, the authors noticed no vaccine-related critical antagonistic occasions in youngsters. There have been no indicators of MIS-C, myocarditis, or pericarditis.

In comparison with younger adults who obtained a 100-μg dosage of the mRNA-1273 vaccine, youngsters receiving a 50-μg dosage had larger neutralizing antibody (nAb) titers. The nAB titers in youngsters vs. younger adults have been 1610 and 1300, respectively, put up one month of receiving the second dose, i.e., day 57. Furthermore, the magnitude of the geometric imply titer (GMT) of nAbs at day 57 properly correlated with a 69% lowered COVID-19 threat within the COVE trial. Moreover, 99% of each age group individuals confirmed serologic responses, pointing to the success of the pre-specified non-inferiority criterion.

It’s noteworthy that in opposition to any incidence of COVID-19 inside 14 days put up first vaccine dose, first injection, the vaccine efficacy was 88.0%, in response to the Facilities for Illness Management and Prevention (CDC) definition. This research remark corresponds to the time when SARS-CoV-2 Delta (B.1.617.2) variant was dominant within the US.


The current research introduced the interim outcomes of the continuing KidCOVE trial. The findings demonstrated {that a} 50-μg dose stage of the mRNA-1273 vaccine supplied a protecting profit in youngsters aged six to 11 years in opposition to SARS-CoV-2 and its variants starting 14 days after the primary injection. Moreover, it had an appropriate security profile and excessive efficacy.

Journal reference:
  • Analysis of mRNA-1273 Covid-19 Vaccine in Kids 6 to 11 Years of Age, C. Buddy Creech, Evan Anderson, Vladimir Berthaud, Inci Yildirim, Andrew M. Atz, Ivan Melendez Baez, Daniel Finkelstein, Paul Pickrell, Judith Kirstein, Clifford Yut, Ronald Blair, Robert A. Clifford, et al.. The New England Journal of Medication. doi: 10.1056/NEJMoa2203315



Leave a Reply